Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
And from my SA news feed: Shares of InterMune (ITMN +14.3%) spike on a 2x surge in volume in response to rumors that Roche (OTCQX:RHHBY +0.4%), Sanofi (SNY +0.7%), Glaxo (GSK -0.1%) and Actelion (OTCPK:ALIOF) (OTC:ACIOY) are preparing offers. Trading in ITMN shares was halted briefly at 1:00 pm EDT due to abnormal volatility.
Fergo, Haven't heard anything. Suspect this attempt is more likely to work but perhaps the European biggies see enough $$$ ahead in Europe, with the US being a very tasty icing on the cake. Steve
Fergo,
Yes, that's the Bloomberg story I just saw. As it at first traded over 54 and is now down to 51, it seems to have been taken seriously but perhaps the first high prices were a bit too enthusiastic. Maybe someone is reassessing what the bids are likely to come in at.
Steve
And the stories have now shown up on Bloomberg and Reuters.
Big jump in price today, to the 53-54 area. Impending news of a buyout? Haven't found any released news myself.
I agree, having invested in several Frost stocks but only after doing some DD to verify something being "there," other than just Frost. This one is likely much more independent of his magic touch than are those in the life sciences, where his skill at cobbling disparate chunks of business into the next Ivax might be essential..
Miles,
Yes, overvalued for what we "know" about it now. But it is an interesting lottery ticket, so I bought a few at .15 when they became available.
Steve
Sun,
I would speculate that people are interested in the $NNAB shares - if they are cheap enough - as lottery tickets. There was some speculation on another site that these two kids have the benefit of "smart" genes, given who their fathers are and that the dads, as part owners, might park some new IP here.
Steve
Looks like we are now Alpine Biosciences - by acquiring and merging with them.
IMHO, when the first patient gets seriously ill from one of the generic products, TEVA will have a field day and tweak the FDA over their refusal to test the generics for bioequivalence.
However, it would be better for TEVA to buy the rights to Trimesta.
And see, back up. .... Somewhat.
We're not there yet.
Hoping we never go as low as $7 again.
Thank you for posting that.
Good articles today. In addition to comparing treatments for melanoma, you might consider an article on companies with the IP to pursue electroporation, what are their limits and focus, etc.... Clearly $ONCS would be right up there.
Happy to do it. Some day, we shareholders will get something good.
Edit: Though I did double up.
Gary,
Thanks for the update. Glad to hear they were conservative in recording the revenue from Hamamatsu sales and did not record the revenue as quickly as a fly-by-night firm would.
Steve
I sold at the time as well, instead of waiting. Still, as we owned the stock during the window they discussed, I thought it at least remotely possible there might be something in it for us. Hence I read the crap they sent out and called.
Scientifically yes. Still need to meet with FDA to go beyond the mouse trials and start with safety studies in people. We'll have to see how soon $MNOV designs its trials and meets with FDA.
Starbuxsux,
After 18 days of no response from the law firm, I called again yesterday. This time I did get an answer and, as I expected, only the attorneys get their fees. We shareholders get nothing monetary.
Ambulance chasers looking out only for themselves.
Steve
MediciNova Announces Positive Results of MN-001 in Advanced NASH Mouse Model; MediciNova Requests a Meeting With FDA
http://finance.yahoo.com/news/medicinova-announces-positive-results-mn-113000573.html
MN-001 showed anti-NASH and anti-fibrotic effects in the advanced NASH mouse model. NAFLD activity score was significantly reduced in the MN-001 treated group compared to the non-treated group (p<0.001). The reduction was observed consistently in all NAS components including hepatocyte ballooning score (p<0.001), lobular inflammation score (p<0.01), and steatosis score (p<0.05). Percent fibrosis area was also reduced in the MN-001 treated group (p<0.01). In addition, alpha-SMA-positive staining area was significantly reduced in the MN-001 treated group (p<0.001).
Based on these results in addition to the results of the first NASH mouse model study reported on January 14, 2014, MediciNova requested a meeting with FDA to finalize the trial design for a clinical study of MN-001 in NASH patients.
Or it may be time to average down.
It will be interesting, especially with the general downdraft against most biotech stocks. $ITMN is one that has been one of the few exceptions.
All good questions, to which any long should seek answers. There is so much DD on this board regarding $ONCS. My own practice, when I research new stocks, is to read at least the last 200 posts as a start on my own DD.
RadOncoGirl,
I have a similar number of shares and similar cost basis in $ONCS as you. I think you (we) picked a future winner here in $ONCS and I especially appreciate that you did this with your oncology background.
However, your question regarding why someone would bid low is a rookie investor question. Personally, with nearly 50 years of investing under my belt (still making rookie mistakes too), I feel that even a low bid for $ONCS provides some support for the price and a greater potential reward for the buyer, as price fluctuates. Perhaps the stress of how $ONCS price has been under pressure makes some of us respond in less than a respectful manner. I think Jbem did point you toward a site offering basic investor information, although IHub also has boards providing basic information.
GLTAL and to our investment in $ONCS.
Steve
(GLTAL is Good Luck To All Longs)
Amen to that!
Good day to be long!
From a quick reading, I think $ICOTF is rather peripheral to all of this stuff in the PR, mentioned only because they licensed a drug to Immune Pharma. I guess they don't have much to tell us at this time.
EDIT: Aha. The drug licensed from ICOTF is the one under development to treat this disease.
Picked up another 10k shares at $1.65.
Ima,
Thanks for the explanation.
Steve
It is great that there was a statistically-significant improvement for the experimental group (VGX-3100 + electroporation), but I wonder what the explanation is for the control group (placebo + electroporation) to have had a 30 percent improvement. I would have thought that they would have been closer to zero effect. Any ideas?
Is there some potential that the electroporation itself had this positive effect (the 30 percent)?
Good to hear! Thanks for posting that.
cw, I have a free membership and can't pm, but thank you for the response. Steve
Just out of curiosity, were those pre or post r/s prices?
Also, how do you feel INO has changed? Do you feel the periodic bear attacks - citing what I would consider ancient history under old management - to be unwarranted?
That is a display of patience with a capital P.
OK. Thank you. Looking forward to what you find.
Curious,
Take your time doing the DD. There is NO rush. As part of your DD, you might like to read the various articles by Jason Napodano on Seeking Alpha on ICOTF. He was very bullish and provided quite lucid explanations of the science and potential. After the study results were published he explained the failure and was rather more sanguine about it's prospects.
If his articles are no longer available, give me your email (I don't pm, but if you either have a paid account or use happy hour on friday, you can send it that way) and I'll try to email you the pdf copies I saved on my PC.
Disclosure: I am holding what I have, but too many of my other biotechs with upcoming catalysts are taking a beating to add here.
Steve
The results of one study were way below what was expected. For example, see:
http://ih.advfn.com/p.php?pid=nmona&article=62494545
Will do so.